Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

790
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
790
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Prodrugs01:30

Prodrugs

3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.

Parkinsonism & related disorders·2005
Same author

Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.

Journal of neural transmission (Vienna, Austria : 1996)·2004
Same author

Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.

Parkinsonism & related disorders·2003
Same author

Co-occurrence of essential tremor and Parkinson's disease: clinical study of a large kindred with autopsy findings.

Parkinsonism & related disorders·2003
Same author

Intrastriatal iron perfusion releases dopamine: an in-vivo microdialysis study.

Journal of neural transmission (Vienna, Austria : 1996)·2002
Same author

Parkinsonism: onset, progression, and mortality. 1967.

Neurology·2002

Related Experiment Video

Updated: Jan 9, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.3K

Levodopa.

M D Yahr

    Annals of Internal Medicine
    |November 1, 1975
    PubMed
    Summary

    Levodopa is the most effective treatment for Parkinson symptoms, offering sustained relief and reduced mortality with long-term safety. Careful patient monitoring is essential due to potential side effects.

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Parkinson's disease and postencephalitic parkinsonism are debilitating neurological disorders.
    • Levodopa is a primary therapeutic agent for managing Parkinsonian symptoms.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Levodopa in managing Parkinson symptoms.
    • To explore potential novel applications of Levodopa in other neurological and endocrine conditions.

    Main Methods:

    • Review of clinical data on Levodopa efficacy and safety in Parkinson's disease.
    • Analysis of long-term Levodopa administration outcomes.
    • Exploration of emerging research on Levodopa's use in hepatic encephalopathy, pituitary disorders, and Huntington's chorea.

    Main Results:

    More Related Videos

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.3K
    Ole Isacson: Development of New Therapies for Parkinson's Disease
    23:53

    Ole Isacson: Development of New Therapies for Parkinson's Disease

    Published on: April 29, 2007

    8.4K

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    4.3K
    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    3.3K
    Ole Isacson: Development of New Therapies for Parkinson's Disease
    23:53

    Ole Isacson: Development of New Therapies for Parkinson's Disease

    Published on: April 29, 2007

    8.4K
    • Levodopa demonstrates significant efficacy in controlling Parkinson symptoms, leading to sustained therapeutic responses.
    • Long-term Levodopa use (over five years) shows sustained benefits and a decreased mortality rate.
    • Levodopa is generally safe for long-term use, though careful patient screening and monitoring are crucial due to potential side effects.

    Conclusions:

    • Levodopa remains the gold standard for Parkinson symptom management, offering significant long-term benefits.
    • While established for Parkinsonism, Levodopa shows promise for hepatic encephalopathy, pituitary disorders, and Huntington's chorea, pending further research and FDA approval.